OpGen, Inc. (OPGN)
| Previous close | 0.4604 |
| Open | 0.4665 |
| Bid | 0.4352 x 1000 |
| Ask | 0.4420 x 1000 |
| Day's range | 0.4300 - 0.4665 |
| 52-week range | 0.1650 - 9.0600 |
| Volume | |
| Avg. volume | 4,576,601 |
| Market cap | 4.797M |
| Beta (5Y monthly) | -0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.2500 |
| Earnings date | 14 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G
- GlobeNewswire
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to pur
- GlobeNewswire
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “
